Atsena Therapeutics and Nippon Shinyaku have formed an exclusive licensing agreement for ATSN-101, a gene therapy for Leber ...

In June 2024, a canalicular gel device (Lacrifill, Nordic Pharma) was introduced to the US market, and a recent study has ...

FDA clearance of HG202 marks a significant milestone for CRISPR/Cas13 RNA-editing in clinical applications for nAMD. The ...

Peking University researchers have developed a deep learning-based, noninvasive choroidal angiography method that enables ...

A Johns Hopkins study reveals that anti-VEGF treatments for wet AMD may unintentionally elevate ANGPTL4, a protein that ...

FELIQS plans to conduct a Phase 1b/2 study of FLQ-101 (tROPhy-1 study) both in the US and Japan in the first quarter of 2025.

The Valeda Light Delivery System is for the treatment of patients with dry age-related macular degeneration (AMD).

They received a $6.4 million grant to support drug development and IND-enabling toxicology studies. Bispecific drugs act as ...

Formosa Pharmaceuticals has announced the completion and top-line results from CPN-303, a phase 3 clinical study of APP13007 ...

The investigators explained that AMN, a rare disease, is characterized by dark reddish, wedge-shaped macular lesions. 2 ...

The investigators conducted a randomized controlled trial of 60 patients who underwent monitored anesthesia care sedation for ...

Alfredo Sadun, MD, PhD, is the chief of Ophthalmology at the Doheny Eye Institute of UCLA. At this year's AAO meeting held in ...